Buprenorphine versus domperidone in chemotherapy-induced emesis: a pilot study.
A randomized double-blind cross-over study was performed to evaluate the possible anti-emetic effect of the partial opiate antagonist buprenorphine in comparison to domperidone in chemotherapy-induced nausea and vomiting. Emesis was of significantly shorter duration on domperidone treatment. Most patients preferred domperidone, mainly due to adverse side-effects of buprenorphine. Nevertheless, emesis in buprenorphine treatment was less disabling. Therefore, it might be useful to search for new alternatives in this group of drugs or to use them in a combination regimen of anti-emetic agents.
D000328:Adult; D000368:Aged; D000932:Antiemetics / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects; D002047:Buprenorphine / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004294:Domperidone / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009019:Morphinans / Q000627:therapeutic use*; D009325:Nausea / Q000139:chemically induced / Q000188:drug therapy; D010865:Pilot Projects; D011897:Random Allocation; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy*
D000932:Antiemetics; D000970:Antineoplastic Agents; D009019:Morphinans; D002047:Buprenorphine; D004294:Domperidone